47.69
0.57 (1.21%)
| Previous Close | 47.12 |
| Open | 48.17 |
| Volume | 316,781 |
| Avg. Volume (3M) | 543,659 |
| Market Cap | 1,766,316,032 |
| Price / Earnings (Forward) | 36.36 |
| Price / Sales | 5.71 |
| Price / Book | 30.89 |
| 52 Weeks Range | |
| Earnings Date | 9 Mar 2026 |
| Profit Margin | -10.19% |
| Operating Margin (TTM) | -23.48% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 38.30% |
| Total Debt/Equity (MRQ) | 410.02% |
| Current Ratio (MRQ) | 0.910 |
| Operating Cash Flow (TTM) | 2.09 M |
| Levered Free Cash Flow (TTM) | -26.88 M |
| Return on Assets (TTM) | 0.90% |
| Return on Equity (TTM) | -37.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Harrow, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -3.5 |
| Average | -0.50 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 15.07% |
| % Held by Institutions | 57.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 91.00 (Cantor Fitzgerald, 90.82%) | Buy |
| Median | 80.50 (68.80%) | |
| Low | 70.00 (HC Wainwright & Co., 46.78%) | Buy |
| Average | 80.50 (68.80%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 39.22 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 04 Mar 2026 | 91.00 (90.82%) | Buy | 39.22 |
| HC Wainwright & Co. | 04 Mar 2026 | 70.00 (46.78%) | Buy | 39.22 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | - | 54.18 | -5,000 | -270,900 |
| Aggregate Net Quantity | -5,000 | |||
| Aggregate Net Value ($) | -270,900 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 54.18 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| OPALEYE MANAGEMENT INC. | 27 Feb 2026 | Sell (-) | 5,000 | 54.18 | 270,900 |
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |